Illustrative image – not actual.
SMS Pharmaceuticals, a Hyderabad-based pharmaceutical company, with interests in active pharmaceutical ingredients (API) and intermediates has earmarked and will undertake capex of approx. Rs 150 crore in FY25, mainly for backward integration and new product lines.
The investment is aimed at enhancing its production capabilities and introducing new products, while optimising costs, enhancing operational efficiencies, and leveraging the growth in various product segments. Also, its R&D efforts are geared towards development in high-demand therapeutic areas, for a robust pipeline for future growth. This capex will be funded by a combination of internal accruals, term loan and the recent fundraise through equity warrants of Rs 114.3 crore.
In FY24, the company witnessed robust growth across all its product segments. The strategic diversification and backward integration has significantly contributed to maintaining stability in its product portfolio. Also, the ARV segment's contribution to the top line was around 20 percent for the full year, and will cater to the demand for such products in future.
